دورية أكاديمية
Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom
| العنوان: | Budget impact analysis of betrixaban for venous thromboembolism prophylaxis in nonsurgical patients with acute medical illness in the United Kingdom |
|---|---|
| المؤلفون: | Guy, Holly, Laskier, Vicki, Fisher, Mark, Bucior, Iwona, Deitelzweig, Steven, Cohen, Alexander T. |
| بيانات النشر: | Taylor & Francis |
| سنة النشر: | 2019 |
| المجموعة: | The University of Queensland: UQ eSpace |
| مصطلحات موضوعية: | Betrixaban, budget impact, prophylaxis, UK, venous thromboembolism, 2719 Health Policy, 2736 Pharmacology (medical) |
| الوصف: | Objectives: Venous thromboembolism (VTE) incurs substantial costs to the UK National Health Service (NHS). Betrixaban is approved in the US for VTE prophylaxis with a recommended 35–42 days of treatment. This analysis modeled the budget impact of introducing betrixaban for extended-duration VTE prophylaxis in nonsurgical patients with acute medical illness at risk of VTE in the UK, where it is not yet licensed. Methods: The 5-year budget impact of introducing betrixaban into current prophylaxis (low molecular weight heparin and fondaparinux) was estimated for the UK NHS. The Phase 3 APEX study provided primary event (VTE, myocardial infarction, ischemic stroke, and death; all-cause or VTE-related) and treatment complications data. Literature informed risk of recurrent events and long-term complications, population, market share, and costs for treatment and management of events. Network meta-analyses informed symptomatic DVT, pulmonary embolism and VTE-related death rates in fondaparinux patients. Deterministic sensitivity analyses explored uncertainty. Results: Introducing betrixaban accrued savings of £1,290,000-£23,000,000 in years 1–5. Savings were from reduced primary VTE events, which reduced recurrent events and future complications. All sensitivity analyses showed savings. Conclusion: Introducing extended-duration VTE prophylaxis with betrixaban in the UK would accrue substantial savings annually over the next 5 years compared to current prophylaxis. Clinical trial registration: www.clinicaltrials.gov identifier is NCT01583218. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| تدمد: | 1744-8379 1473-7167 |
| العلاقة: | Not set |
| الإتاحة: | https://doi.org/10.1080/14737167.2019.1629905Test https://espace.library.uq.edu.au/view/UQ:a9e82d4Test |
| رقم الانضمام: | edsbas.B9406FB6 |
| قاعدة البيانات: | BASE |
| تدمد: | 17448379 14737167 |
|---|